Get the Stockscreener App
40.29
1.44%
0.57
After Hours:
39.90
-0.39
-0.97%
Grail Inc stock is traded at $40.29, with a volume of 551.39K.
It is up +1.44% in the last 24 hours and down -12.74% over the past month.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
See More
Previous Close:
$39.72
Open:
$39.76
24h Volume:
551.39K
Relative Volume:
0.39
Market Cap:
$1.45B
Revenue:
$117.67M
Net Income/Loss:
$-1.88B
P/E Ratio:
-0.6655
EPS:
-60.5369
Net Cash Flow:
$-621.36M
1W Performance:
+14.49%
1M Performance:
-12.74%
6M Performance:
+40.82%
1Y Performance:
+154.28%
1-Day Range:
$39.01
$40.62
1-Week Range:
$33.73
$41.22
52-Week Range:
$12.33
$63.99
Grail Inc Stock (GRAL) Company Profile
Name
Grail Inc
Sector
Industry
Phone
(833) 694-2553
Address
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
40.29 | 1.43B | 117.67M | -1.88B | -621.36M | -60.54 |
|
TMO
Thermo Fisher Scientific Inc
|
478.32 | 179.32B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
205.48 | 145.22B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
565.19 | 44.23B | 3.93B | 894.97M | 837.70M | 10.82 |
|
IQV
Iqvia Holdings Inc
|
199.17 | 34.14B | 15.50B | 1.33B | 2.16B | 7.34 |
|
A
Agilent Technologies Inc
|
120.18 | 34.19B | 6.63B | 1.17B | 1.19B | 4.05 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Canaccord Genuity | Buy |
| Nov-27-24 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-24 | Initiated | Guggenheim | Neutral |
Grail Inc Stock (GRAL) Latest News
What institutional investors are buying GRAIL LLC stockRapid portfolio appreciation - jammulinksnews.com
What markets is GRAIL LLC expanding into Is Cadiz Inc. stock a good long term investment optionDiscover high-impact stocks for your portfolio - jammulinksnews.com
How strong is GRAIL LLC company’s balance sheetBuild a portfolio with strong long-term growth - jammulinksnews.com
Is GRAIL LLC a good long term investmentExplosive earning power - PrintWeekIndia
What analysts say about GRAIL LLC stockFree Stock Market Real-Time Monitoring - PrintWeekIndia
"The Grail Collection" Could Be a Game-Changer for MDCE (OTC:MDCE)Jordan, Curry, and NBA Royalty Up for Bid - ACCESS Newswire
Minimal Residual Disease Testing Market Trends Analysis Report 2025-2030 | North America Leads in MRD Testing Market with Advanced Reimbursement Ecosystem - GlobeNewswire Inc.
GRAIL LLC Stock Analysis and ForecastBreakout portfolio performance - Autocar Professional
What drives GRAIL LLC stock priceHigh-yield trading alerts - Autocar Professional
Freenome's new CEO is ready to compete in race for tests that can detect cancer earlySan Francisco Business Times - The Business Journals
(GRAL) Technical Data - news.stocktradersdaily.com
Grail posts latest trial data for Galleri cancer detection test - MSN
Grail’s CFO Freidin sells $311k in common stock By Investing.com - Investing.com India
Grail’s CFO Freidin sells $311k in common stock - Investing.com Australia
Grail (GRAL) PT Hiked to $38 at Morgan Stanley amid ‘Equal Weight’ Stance - MSN
GRAIL’s Galleri Multi-Cancer Test Shows Strong Performance in PATHFINDER 2 Study, Paves Way for FDA Submission - MSN
12 Best Young Stocks To Buy and Hold For 5 Years - Insider Monkey
Illumina: A Compelling Buy Despite GRAIL Divestiture and Macroeconomic Challenges - AInvest
Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds - Seeking Alpha
Grail (GRAL): A High-Reward, High-Risk Play on Cancer Detection's Future - AInvest
15 Successful Spin-Off Companies and Their 2025 Returns - Insider Monkey
GRAIL Insiders Selling US$10m In Stock Relieved As Market Cap Slides To US$1.7b - simplywall.st
GRAIL's Insider Sales: Red Flag or Strategic Move? Assessing Executive Confidence Amid Strong Financials - AInvest
(GRAL) Trading Report - news.stocktradersdaily.com
GRAIL, Inc.(NasdaqGS: GRAL) added to Russell 2500 Value Index - MarketScreener
GRAIL, Inc.(NasdaqGS: GRAL) dropped from Russell Midcap Index - MarketScreener
Galleri Early Detection Test May Improve Cancer Detection vs SOC Alone - CancerNetwork
Morgan Stanley raises Grail stock price target to $38 on cancer test potential - Investing.com
Grail plans FDA filing for cancer blood test after new trial - pharmaphorum
Grail reports positive outcomes from registrational study of Galleri test - Yahoo Home
PATHFINDER 2 Trial Releases Positive Topline Data for Multicancer Early Detection Test - OncLive
Grail plans to submit updated Galleri blood test for FDA approval next year - Fierce Biotech
Grail stock gains on new data for Galleri cancer test (GRAL) - Seeking Alpha
GRAIL reports positive results from cancer detection test study By Investing.com - Investing.com Nigeria
GRAIL reports positive results from cancer detection test study - Investing.com Australia
GRAIL Announces Positive Top-Line Results From The Galleri PATHFINDER 2 Registrational Study - MarketScreener
Grail reports results from PATHFINDER 2 study - TipRanks
Revolutionary Cancer Screening Test Achieves Major Clinical Success: GRAIL's Galleri Outperforms Previous Study - Stock Titan
GRAL Stock Surges: What Drives the Excitement? - timothysykes.com
GRAIL: Too Much A Leap Of Faith (NASDAQ:GRAL) - Seeking Alpha
California State Teachers Retirement System Takes $464,000 Position in Grail, Inc. (NASDAQ:GRAL) - Defense World
67,288 Shares in Grail, Inc. (NASDAQ:GRAL) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Grail Inc Stock (GRAL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.50%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):